Clinical trial Recruiting at 1 site Interventional Ages 18 and up Women only

New [18F]-FES PET/CT imaging to detect and describe endometriosis lesions

Official title: 18F]-FES PET in the Detection and Characterization of Endometriosis Lesions

Run by University Hospital, Toulouse · NCT07053982 · Data updated 2026-11-12

This study will test whether an [18F]-FES PET/CT scan can better find endometriosis lesions and measure estrogen receptor activity in adults scheduled for surgery.

More Endometriosis trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment20 (estimated)
SponsorUniversity Hospital, Toulouse
Academic / other
Locations1 site (Toulouse)
StatusRecruiting
StartedMarch 23, 2026
Main results expectedMarch 2028
Study endsMarch 2028
Registry record updatedMarch 25, 2026
Trial IDNCT07053982 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 18 undergoing surgery for endometriosis who can have a preoperative MRI and [18F]-FES PET/CT, are not menopausal or on hormone therapy, and can provide informed consent are ideal candidates.

Probably not a fit

Patients who are pregnant, menopausal, currently on hormone therapy, managed without surgery, claustrophobic, or allergic to the tracer are unlikely to benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants will undergo a preoperative [18F]-FES PET/CT scan in addition to standard MRI, with images compared to surgical and pathology findings to locate and characterize lesions. The study will correlate PET uptake with tissue estrogen receptor expression measured on surgical specimens and with patient-reported pain intensity. Enrollment includes symptomatic cases (VAS ≥ 4) and control patients treated surgically for infertility (VAS < 4), with imaging performed mid-cycle when possible. The approach aims to determine whether [18F]-FES PET/CT improves lesion detection and provides quantitative receptor information that could guide treatment.

Why it matters

Potential benefit: If successful, the test could improve diagnostic accuracy, shorten diagnostic delay, and help personalize hormonal treatment by showing lesion estrogen receptor expression.

How similar studies have gone: [18F]-FES PET/CT has shown good correlation with estrogen receptor expression in breast cancer, but its application to endometriosis is novel and data are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Cases:

\- Painful patients with a VAS ≥ 4 treated surgically for painful symptoms related to endometriosis;

Controls:

* Patient with a VAS \< 4 treated surgically for endometriosis in the context of infertility;
* Age \> 18 years;
* Patient who provided informed consent;
* Patients who underwent a preoperative MRI and were not contraindicated for \[18F\]-FES PET/CT;
* Patient who underwent surgery mid-cycle;
* Affiliation to a social security scheme

Exclusion Criteria:

* Patient treated for endometriosis without surgery;
* Pregnant patient
* Patient taking hormone therapy
* Menopausal patient
* Hypersensitivity to the active substance (Fluoroestradiol (18F)) or to any of the excipients
* Patient under legal protection
* Claustrophobic patient

Where it's running

  • Toulouse, Rangueil Hospital
    Toulouse, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.